68701-47-3

Usage

Structure

Amino acid derivative with a cyclopropyl group attached to the benzene ring

Natural Occurrence

Not naturally occurring

Primary Use

Research chemical and biochemical tool

Applications

Medicinal chemistry and pharmaceutical research, particularly in drug development targeting specific biological receptors

Unique Properties

Valuable tool in the study of structure-activity relationships and receptor-ligand interactions

Upstream product

• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 1119088-76-4 methyl 2-amino-5-cyclopropylbenzoate 
• 68701-46-2 N-(2-cyano-4-cyclopropylphenyl)acetamide 
• 19936-11-9 N-(4-cyclopropylphenyl)acetamide 
• 68701-45-1 N-(2-bromo-4-cyclopropylphenyl)acetamide 

Downstream Products

• 1119085-43-6 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid 
• 1119084-96-6 5-cyclopropyl-2-(2-phenylpyrimidin-5-ylamino)benzoic acid 

Relevant academic research and scientific papers

AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS

New azabiphenylaminobenzoic acid derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH)

(E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents

A series of substituted (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids was prepared and evaluated in the rat passive cutaneous anaphylaxis (PCA) test for antiallergic activity. Alkoxy, alkylthio, and isopropyl substituents at the 6- or 8-positions provided highly potent compounds. Conversion to the Z isomer, reduction of the side chain double bond, or reduction of the quinazoline ring resulted in substantial loss of activity. Among the analogues that exhibited oral activity in the PCA test, (E)-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid was the most potent.

Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of inhibiting allergic reactions with them

Pyrido[2,1-b]quinazolines of the formulas STR1 wherein R1, R1 ', R2, R2 ', R3, R3 ', R4 and R10 are as hereinafter set forth, and processes for the preparation thereof